A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 With BGB-A317 in Subjects With B-Cell Lymphoid Malignancies
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2016
At a glance
- Drugs BGB 3111 (Primary) ; BGB A317 (Primary)
- Indications B cell lymphoma; Leukaemia
- Focus Adverse reactions
- Sponsors BeiGene
- 11 Nov 2016 According to a BeiGene media release, data from this trial is anticipated to be presented in 2017.
- 29 Jun 2016 According to a BeiGene media release, the first patient has been enrolled in this trial.
- 08 Jun 2016 Status changed from planning to recruiting.